Fc-optimized checkpoint antibodies for cancer immunotherapy

Rony Dahan; Alan J. Korman

doi:10.1016/j.molmed.2024.10.008

Fc-optimized checkpoint antibodies for cancer immunotherapy

Rony Dahan, Alan J. Korman

Department of Systems Immunology

Weizmann Institute of Science

Research output: Contribution to journal › Short survey › peer-review

Abstract

The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.

Original language	English
Pages (from-to)	501-505
Number of pages	5
Journal	Trends in Molecular Medicine
Volume	31
Issue number	6
DOIs	https://doi.org/10.1016/j.molmed.2024.10.008
State	Published Online - 1 Nov 2024

All Science Journal Classification (ASJC) codes

Molecular Medicine
Molecular Biology

Access to Document

10.1016/j.molmed.2024.10.008

Cite this

@article{19f2c5764fcc4863a855c3c15bbc1bf5,

title = "Fc-optimized checkpoint antibodies for cancer immunotherapy",

abstract = "The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.",

author = "Rony Dahan and Korman, \{Alan J.\}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = nov,

day = "1",

doi = "10.1016/j.molmed.2024.10.008",

language = "الإنجليزيّة",

volume = "31",

pages = "501--505",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Fc-optimized checkpoint antibodies for cancer immunotherapy

AU - Dahan, Rony

AU - Korman, Alan J.

PY - 2024/11/1

Y1 - 2024/11/1

N2 - The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.

AB - The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.

UR - http://www.scopus.com/inward/record.url?scp=85207745061&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2024.10.008

DO - 10.1016/j.molmed.2024.10.008

M3 - عرض مختصر

SN - 1471-4914

VL - 31

SP - 501

EP - 505

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 6

ER -

Fc-optimized checkpoint antibodies for cancer immunotherapy

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this